Efferalgan Vit. C

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Efferalgan Vit. C

Property Description
Active ingredient Acetaminophen (Paracetamol), Sodium Ascorbate (Vitamin C)
Form Effervescent tablets
Pharmacological class Non-opioid analgesic and antipyretic agent, vitamin supplement
Common use Symptomatic relief of pain and fever during cold or flu-like conditions
Origin Predominantly synthetic preparation

Efferalgan Vit. C is a clinically recognized fixed-dose combination product containing the active ingredients Acetaminophen (or Paracetamol) and Sodium Ascorbate (Vitamin C), primarily used for the symptomatic relief associated with common discomforts such as headaches or malaise. This pharmaceutical entity integrates the actions of a central-acting pharmacological agent with an essential nutrient, offering a distinctive feature over simple, single-ingredient analgesics. The product is a predominantly synthetic preparation, supplied as effervescent tablets for oral administration.


What Type of Medicine is Efferalgan Vit. C?

Efferalgan Vit. C is classified as a non-opioid analgesic and antipyretic agent combined with a complementary vitamin supplement. Acetaminophen, the analgesic component, is categorized under the World Health Organization's Anatomical Therapeutic Chemical (ATC) system as N02BE01. As a pain reliever and fever reducer, Paracetamol acts centrally in the nervous system. This medicine is specifically designed to manage the perception of pain and help control the body's internal temperature regulation.

The use of the effervescent tablet form is a key differentiator, distinguishing it from solid tablet formulations. It ensures the active ingredients are fully dissolved prior to ingestion; liquid forms facilitate a rapid initial absorption compared to standard solid-dose preparations.


Composition: Acetaminophen, Sodium Ascorbate, and General Purpose

The medicine's composition is based on the synergy between its two active components. The Acetaminophen component is the core pharmacological agent, designed to provide relief from mild-to-moderate pain and to achieve fever reduction by inhibiting specific prostaglandin synthesis centrally. The second component, Sodium Ascorbate (a salt form of Vitamin C), is an essential micronutrient recognized for its function as an antioxidant, playing a crucial role in supporting normal metabolic processes and overall resilience during illness. The general therapeutic purpose is thus to provide simultaneous symptomatic relief of discomfort and vital nutritional support, making it suitable for managing a seasonal cold with accompanying fever and body aches.

Regulatory References

  1. MedlinePlus Vitamin C

What side effects are possible with Efferalgan Vit. C?

The safety profile for this medicine is based on the regulatory documentation for its primary pharmacological component, Paracetamol (Acetaminophen), and is classified by frequency and body system as documented by government health authorities.

Official Adverse Reactions and System Groupings

Adverse reactions are officially grouped into System-Organ Classes (SOCs). These include Hepatobiliary disorders, Immune System disorders, Blood and Lymphatic System disorders, and Skin and Subcutaneous Tissue disorders.

Most documented adverse events, such as thrombocytopenia (low platelet count), jaundice, nausea, diarrhoea, and allergic reactions, are generally classified as Rare or Very Rare in regulatory documents when the medicine is used at therapeutic doses. More severe effects, like anaphylactic shock or severe blood dyscrasias, are sometimes classified as Not Known frequency.


Serious Safety Considerations and Risk Patterns

The label documents the potential for Serious Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson Syndrome, and the risk of Hepatotoxicity (liver damage). These rare but serious outcomes are the focus of mandatory warnings from regulatory bodies.

Safety constraints exist for specific populations. The medicine is contraindicated in patients with known severe hepatic insufficiency. Patients with severe renal impairment, chronic alcoholism, malnutrition, or low body weight are noted as being at increased risk of hepatotoxicity by government health authorities.

Official safety patterns emphasize that liver damage is strongly associated with acute overdose. Prolonged regular daily use may also affect the action of oral anticoagulants, potentially increasing the risk of bleeding. To avoid accidental overdose, regulatory documents explicitly advise against concurrently taking other Paracetamol-containing products.

Overdose and Emergency Response

The official regulatory profile for the product containing Acetaminophen (Paracetamol) and Vitamin C mandates an immediate and urgent response to any suspected overdose. Overdose manifestations documented in prescribing information often begin with non-specific symptoms such as pallor, nausea, vomiting, anorexia, and general malaise, typically appearing in the first 24 hours.

Documented Severe Outcomes

The most critical documented outcome is delayed, dose-dependent hepatic necrosis, which can progress to life-threatening acute liver failure. Severe poisoning may involve systemic complications, including acute renal tubular necrosis, metabolic acidosis, and, rarely, complications in the central nervous system like encephalopathy. The risk of serious poisoning is specifically noted to be higher in patients with pre-existing hepatic impairment or those with chronic alcoholism or chronic malnutrition.

Mandated Emergency Action

It is an explicit regulatory requirement to seek immediate medical attention and ensure immediate transfer to a hospital for any suspected overdose, even if the individual feels well. This is due to the documented risk of delayed, severe liver damage.

Established management procedures include the timely administration of the specific antidote, N-acetylcysteine (NAC). Additionally, official documents state that treatment with activated charcoal may be considered if the ingestion occurred within the previous hour, and blood sampling for plasma concentration is mandatory for monitoring.

Therapeutic Uses of Efferalgan Vit. C

The primary therapeutic purpose of Efferalgan Vit. C is to provide symptomatic relief across key domains associated with acute, temporary illness. The core analgesic component is commonly used in areas where short-term symptom management is appropriate.


Easing Mild-to-Moderate Pain and Systemic Body Aches

This medication is commonly used to address symptoms related to physical discomfort, particularly headaches and generalized body aches, which are symptoms that create noticeable physiological strain in many acute conditions. It helps manage the intensity of mild-to-moderate pain, which contributes to improved day-to-day comfort during periods when symptoms are more noticeable.

The medication is generally applied in conditions presenting with acute episodes marked by symptoms such as fever, headache, body aches, and malaise.


Controlling Fever and Supportive Benefit

Efferalgan Vit. C is applied in clinical contexts where patients present with symptoms related to systemic imbalance, such as elevated body temperature (fever), during conditions characterized by periods of heightened symptoms like the common cold or flu-like syndromes. The medication helps with fever reduction, which in turn supports general well-being during symptomatic phases by easing the associated malaise and stress. The combination may assist with symptomatic support that helps ease the overall symptom burden and supports patients during difficult episodes by easing distress.

“It is commonly used across domains where short-term symptom management is appropriate, particularly in clinical settings involving concurrent fever and pain.”


Therapeutic Focus: Symptom Management

Efferalgan Vit. C is relevant in conditions where short-term symptomatic assistance is needed for both pain and pyrexia (fever).

Regulatory References

  1. Health Canada Acetaminophen Labelling Standard

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

The eligibility for Efferalgan Vit. C is determined by the regulatory standards for its active ingredient, Paracetamol, and specific considerations for the Vitamin C component and excipients. The regulatory label divides use into permitted, restricted, and contraindicated populations.

Classification Population/Condition
Allowed Use Adults and adolescents weighing 50 kg or more; children weighing 27 kg or more (approximately 8 years of age and above).
Contraindicated Patients with known hypersensitivity to Paracetamol or excipients; individuals with severe liver disease or severe hepatocellular insufficiency.
Contraindicated (High Dose) Individuals with a history of renal lithiasis (kidney stones), especially when using high doses of Vitamin C (above 1 g daily).
Restricted Use Patients with mild to moderate hepatic or renal insufficiency; those with chronic alcoholism or malnutrition; patients on a sodium-reduced diet.
Not Recommended Children weighing less than 27 kg; patients with rare hereditary problems of fructose intolerance.

Pregnancy and Lactation: Use during pregnancy is permitted if clinically necessary, adhering to the lowest effective dose for the shortest duration. The medicine is generally compatible with breastfeeding.

What should I know about interactions with other medicines?

The official regulatory profile for this combination product details specific interaction patterns. Co-administration with any other medicinal product containing Acetaminophen (Paracetamol) is a formally contraindicated combination to prevent the risk of severe hepatotoxicity.

Interactions Affecting Drug Exposure

Certain substances are documented to alter the body's processing of the analgesic component. Enzyme Inducers (such as Barbiturates or Carbamazepine) increase the formation of a toxic Acetaminophen metabolite, which elevates the risk of liver damage. Conversely, the co-administration of Probenecid officially reduces Acetaminophen clearance, resulting in an increase in its plasma concentration.

Pharmacodynamic and Timing Restrictions

A significant pharmacodynamic interaction is documented when Acetaminophen is used regularly with Oral Anticoagulants (e.g., Warfarin). This enhances the anticoagulant effect, increasing the risk of bleeding. Furthermore, the Ascorbic Acid component is subject to an administration-timing rule: it must not be administered within the first month of Desferrioxamine therapy and should be separated by at least two hours if co-administration is necessary.

Alcohol and Diagnostics

Chronic Ethanol (alcohol) consumption is officially classified as an Enzyme Inducer, and this interaction risk is explicitly documented to be heightened in patients with hepatic impairment. Finally, the high content of Ascorbic Acid is documented to cause interference with laboratory tests, specifically resulting in falsely low readings for urinary and serum glucose in certain diagnostic assays.

Mechanism of Action

Modulation of Central Thermoregulatory and Nociceptive Pathways

The main pharmacological action is exerted by Acetaminophen, which acts centrally by inhibiting the peroxidase activity of Cyclooxygenase (COX) enzymes within the brain and spinal cord, specifically where peroxide concentrations are low. This molecular action leads to a reduction of Prostaglandin E2 ( PGE2) synthesis in the hypothalamus, which functionally alters the thermoregulatory set-point. Concurrently, an active metabolite indirectly modulates TRPV1 and CB1 receptors and enhances descending serotonergic signals. This cascade initiates mechanisms for increased heat loss and modulates nociceptive signal transmission.


Support for Cellular Redox Homeostasis

The complementary component, Sodium Ascorbate (Vitamin C), operates as a water-soluble antioxidant. Its mechanism involves acting as an electron donor to neutralize Reactive Oxygen Species (ROS), thereby helping to protect cellular macromolecules from oxidative stress. This action contributes to the maintenance of cellular redox potential and supports the integrity of metabolic and physiological processes.

Dosage and Administration Information

How to Use Efferalgan Vit. C: Official Administration Guidelines

This section summarizes the high-level usage principles for the Efferalgan combination product, focusing strictly on the administration parameters. The medicine is designated for short-term symptomatic use, and its dosing is centrally determined by the Paracetamol component's established limits.

The product is supplied as an effervescent tablet and is intended exclusively for oral use. Correct use requires the tablet to be completely dissolved in a glass of water before the resulting solution is consumed.


Core Administration Constraints

Parameter Official Instruction
Dosing Schedule Adults/Adolescents 50 kg: 500 mg to 1000 mg Paracetamol per dose. The maximum daily dose should generally not exceed 3000 mg Paracetamol (equivalent to 6 tablets) without medical guidance.
Frequency Pattern A minimum interval of 4 hours must be observed between administrations.
Special Timing Due to the Ascorbic Acid component, administration should be avoided late in the day.

Population and Procedural Adjustments

Dosage rules are governed by strict dose ceilings and weight considerations, as is standard for Paracetamol-containing products. For patients with renal impairment, the minimum interval between doses must be extended to 6 or 8 hours depending on the degree of creatinine clearance, a procedural adjustment intended to prevent systemic accumulation. Similarly, for adolescents under 50 kg, dosing is strictly based on body weight calculation, requiring an appropriate weight-based formulation to be utilized. The total Paracetamol intake from this and all other sources must never exceed the 3000 mg daily ceiling in susceptible populations.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Efferalgan Vit. C

This overview summarizes the structure and nature of the clinical research supporting the approved uses of the fixed-dose combination of Acetaminophen (Paracetamol) and Vitamin C (Sodium Ascorbate). This information focuses on the types of studies that exist and what is known about the evidence landscape, rather than offering medical advice or treatment recommendations.


Evidence for Symptomatic Relief of Acute Pain and Fever

Research exploring this combination examined contexts involving outcomes related to physical discomfort and outcomes related to systemic imbalance associated with short-term, acute conditions like the common cold or flu-like syndromes. Studies were designed to measure changes in patient-reported outcomes describing perceived discomfort, such as headache and generalized body aches.

The core evidence for the pain and fever relief component comes from systematic reviews and meta-analyses that consolidate findings from numerous randomized controlled trials (RCTs) exploring outcomes related to pain and fever reduction from the Acetaminophen component alone. This extensive research base was relevant in studies evaluating the component's effect on outcomes related to systemic or functional imbalance. Findings describe patterns observed in the studies related to the short-term evaluation of these acute symptoms.


Research on Duration of Effect and Follow-up

As research focuses on these acute episodes, long-term effects are not fully established and long-term outcomes are not well characterized. Follow-up durations were limited, meaning the research describes group patterns, not personal outcomes regarding long-term effects. There is limited information available for understanding the durability of observed changes or the patterns of use over extended periods.


What Remains Uncertain in the Research

The current evidence landscape highlights several areas where research remains limited or uncertain. Specifically, comparative evidence is lacking for dedicated trials designed to research whether the fixed-dose combination of Acetaminophen and Vitamin C provides an enhanced symptomatic outcome compared to the use of Acetaminophen alone.

Research explored the Vitamin C component's role in this specific combination, including its association with outcomes monitoring physiological strain or stress during illness. However, the direct clinical benefit derived from the Vitamin C inclusion—beyond its role as an essential nutrient—is an area where certainty remains low.

Key Studies & References

  1. Vitamin C for the common cold and pneumonia (Systematic review relevant to Vitamin C's role in severity and duration)
  2. Revised Guidance Document: Acetaminophen Labelling Standard (Relevant for defining studied pediatric populations and short-term use limits)

Frequently Asked Questions (FAQ)

Common questions about Efferalgan Vit. C (FAQ)


Q: Is Efferalgan Vit. C the same as regular Efferalgan, just with vitamin C?

Efferalgan Vit. C is a fixed-dose combination product containing two active ingredients: Paracetamol (Acetaminophen) and Sodium Ascorbate (Vitamin C). The regulatory profile specifies the concurrent use of both agents for symptomatic relief, making it distinct from any single-ingredient version of the medicine.


Q: How quickly should I expect Efferalgan Vit. C to start working?

Pharmacological studies indicate that the effervescent formulation facilitates rapid initial absorption of the active components. The effervescent form is associated with rapid initial absorption compared to standard solid forms.


Q: How long does the effect of one dose of Efferalgan Vit. C usually last?

Official dosing guidelines are structured around the known duration of action of the analgesic component. To maintain the medicine’s effectiveness and safety, a minimum interval of four hours must be respected between administrations.


Q: Are there any known interactions between Efferalgan Vit. C and common cold remedies?

Official documentation formally contraindicates the co-administration of this medicine with any other product that contains Paracetamol (Acetaminophen). Concurrent use creates a heightened risk of accidental overdose and severe liver damage, as many common cold and flu remedies contain Paracetamol.


Q: What is the difference between Efferalgan Vit. C and other common over-the-counter (OTC) pain relievers?

Official classification places this medicine as a non-opioid analgesic and antipyretic agent, combined with a vitamin supplement. The analgesic component acts centrally in the nervous system, which is a key factual difference when compared to non-steroidal anti-inflammatory drugs (NSAIDs) that act primarily in the periphery.


Q: Is it normal to feel a slight stomach upset after taking Efferalgan Vit. C?

Official regulatory documents classify gastrointestinal issues, such as nausea and diarrhoea, as adverse events of Rare or Very Rare frequency. This means these effects are documented but are generally not commonly observed when the medicine is used according to the approved schedule.


Q: Are there any known risks of long-term use of Efferalgan Vit. C?

The medicine is designated for short-term symptomatic use, and official documentation notes that long-term safety and efficacy are not fully established. Additionally, prolonged regular daily use may affect the action of oral anticoagulants.


Q: Does the efficacy of Efferalgan Vit. C depend on the time of day it is taken?

Administration of the medicine is advised to be avoided late in the day due to the Ascorbic Acid component. This is a procedural rule related to the component’s properties, and not a statement related to the impairment of the primary analgesic component's effectiveness.


Q: Does Efferalgan Vit. C interact with herbal supplements like St. John's Wort?

The regulatory label warns that the primary ingredient can interact with certain enzyme-inducing substances. Co-administration with these types of substances may increase the risk of liver damage through the enhanced formation of a metabolite.


Q: What should I do if I accidentally take two different medicines that both contain the same main ingredient as Efferalgan Vit. C?

In the event of an accidental overdose or suspected overdose, it is advised that immediate medical attention be sought. This is recommended even if no noticeable symptoms are present, due to the serious risk of liver damage associated with the main ingredient.


Q: Can individuals with kidney problems use Efferalgan Vit. C?

Patients with mild to moderate renal insufficiency are placed under restricted use. For those with renal impairment, official guidance specifies that the minimum interval between doses should be extended to six or eight hours, depending on the degree of impairment.


Q: What is the maximum number of days Efferalgan Vit. C is generally recommended for continuous use?

The medicine is approved specifically for short-term symptomatic use. Patient guidelines typically specify a maximum duration, such as three to five days, before requiring further consultation with a healthcare professional.


Q: What does the research say about Efferalgan Vit. C's effectiveness compared to its placebo?

Clinical evidence for the medicine's core function has been consolidated through systematic reviews and meta-analyses of randomized controlled trials. These studies confirm that the Paracetamol component is effective in relieving acute pain and reducing fever when evaluated against control groups.


Q: Why is the effervescent form of Efferalgan Vit. C popular?

The effervescent formulation is noted in regulatory documents for facilitating rapid initial absorption of the active ingredients compared to solid-dose preparations. This formulation also assists in the ease of ingestion for the user.


Q: Does the vitamin C in Efferalgan Vit. C affect its primary function?

The medicine's primary analgesic and fever-reducing action is driven by the Paracetamol component. Official research notes that comparative evidence is lacking for dedicated trials showing the combination provides an enhanced symptomatic outcome over Paracetamol alone.


Q: I read about a rare skin reaction; what are the signs to watch for with Efferalgan Vit. C?

Regulatory warnings describe signs that warrant immediate cessation of use, such as a spreading rash, blisters, or lesions that appear on the mouth, throat, eyes, or genital area. These are documented due to the potential for rare, serious skin reactions.


Q: Can people with high blood pressure use Efferalgan Vit. C?

The effervescent form of the medicine contains a measurable amount of sodium. Regulatory warnings specify that patients on a sodium-reduced diet should exercise caution, which is a standard consideration for individuals managing conditions like high blood pressure.


Q: What are the common mistakes people make when using Efferalgan Vit. C?

Warnings in official documentation emphasize three key procedural rules: avoiding concurrent use with other products containing Paracetamol, strictly adhering to the minimum four-hour dosing interval, and ensuring the tablet is fully dissolved in water before consumption.


Q: What is the difference in formulation between the tablet and the effervescent forms of Efferalgan Vit. C?

The effervescent formulation contains specific inactive ingredients and high sodium content necessary for the tablet to dissolve rapidly in water. This contrasts with standard tablets and requires the effervescent form to be fully dissolved before ingestion.


Q: Does Efferalgan Vit. C interact with caffeine or coffee?

The regulatory profile does not list caffeine as a specific food or drug interaction. However, the official label details interactions with certain classes of substances that act as enzyme inhibitors or inducers.


Q: Can Efferalgan Vit. C cause drowsiness or affect my ability to drive?

Official regulatory documentation states that the medicine has no or negligible influence on the ability to drive or operate machinery. This is based on the known safety profile of the active ingredients when used according to the approved schedule.


Q: Do you have to take Efferalgan Vit. C with food?

The regulatory label generally allows for the administration of the medicine without specific regard to the timing of meals. There is no official requirement to take the dissolved solution with food.


Q: Is Efferalgan Vit. C gluten-free?

The regulatory document's list of inactive ingredients typically does not list gluten-containing compounds. Information about specific excipients should be reviewed in the official documentation.


Q: Is Efferalgan Vit. C a prescription medicine or over-the-counter?

The medicine is classified by regulatory authorities as a non-prescription, or over-the-counter (OTC), medicine. It is intended for self-medication for the short-term relief of symptoms.


Q: I feel a tingling sensation after taking it; is this a known side effect of Efferalgan Vit. C?

Official lists of documented adverse events categorize side effects by system-organ class. Tingling sensations (paresthesia) are not typically listed among the commonly or rarely reported adverse effects documented for this medicine.


Q: Does Efferalgan Vit. C contain sugar or artificial sweeteners?

The official formulation lists all excipients (inactive ingredients) in the medicine. These may include sweeteners, such as aspartame or saccharin, or other compounds that can be sources of sugar.


Q: Are there different strengths of Efferalgan Vit. C available?

The official regulatory document lists the specific marketed strengths of the active ingredients (Paracetamol and Ascorbic Acid) that are approved for public sale and dispensing.


Q: What happens if I miss a scheduled time to use Efferalgan Vit. C?

Official guidelines specify that a missed dose should not be compensated for by taking a double dose. The patient should proceed to take the next scheduled dose at the appropriate time, ensuring the minimum time interval is respected.


Q: Are there official restrictions on who can purchase Efferalgan Vit. C?

As an over-the-counter product, its sale is subject to official regulatory restrictions regarding the maximum pack size and quantity that can be purchased in a single transaction. These restrictions are intended to prevent the risk of accidental overdose.


Q: Can Efferalgan Vit. C affect my sleep patterns?

Official lists of documented adverse events categorize effects on the nervous system and psychiatric disorders. Insomnia or disturbances in sleep patterns are not typically listed among the commonly or rarely reported adverse effects of the primary active ingredient.

How should Efferalgan Vit. C be stored and disposed of?

How to Store and Dispose of Efferalgan Vit. C

Efferalgan Vit. C (Paracetamol and Ascorbic Acid) must be stored according to regulatory requirements to ensure stability and safely disposed of when expired or unused.

Official Storage Requirements

Condition Requirement
Temperature Controlled room temperature, 15 C to 30 C (59 F to 86 F). Do not freeze.
Protection Keep in a cool, dry place; must be protected from moisture.
Container Store in its original container and keep it tightly closed.
Safety Store out of the reach and sight of children.

Disposal Instructions

Unused or expired medicine must be disposed of according to local regulations. The preferred method is using a drug take-back program or mail-back service. Do not dispose of the medicine by flushing it down the toilet or pouring it into wastewater unless officially instructed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Efferalgan Vit. C found in:

A-Z Index: